Chlamydia pneumoniae and atherosclerosis.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Chlamydia pneumoniae (C. pneumoniae) is a common respiratory pathogen. Many reports have documented the presence of C. pneumoniae in atheromatous coronary arteries, aorta, carotid arteries, and peripheral arteries using a variety of techniques. There is clear experimental evidence that C. pneumoniae can infect macrophages, endothelial cells, smooth muscle cells, and induce the formation of foam cells. Evidence from basic research and epidemiologic studies suggest that C. pneumoniae can induce macrophage foam cell formation by dysregulating native LDL uptake or metabolism (or both). Relatively small, secondary prevention studies, have suggested that antibiotic therapy might reduce monocyte activation and C. pneumoniae antibody titers, reduce inflammatory markers and possibly reduce adverse cardiovascular events. It is possible that C. pneumoniae enhances atherogenesis by causing inflammation and eliciting immune responses and may be one of the factors contributing to this multifactorial disease process.

Original languageEnglish (US)
Pages (from-to)218-225
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume2
Issue number3
StatePublished - May 2000

Fingerprint

Chlamydophila pneumoniae
Atherosclerosis
Foam Cells
Macrophages
Secondary Prevention
Carotid Arteries
Smooth Muscle Myocytes
Aorta
Epidemiologic Studies
Monocytes
Coronary Vessels
Endothelial Cells
Arteries
Anti-Bacterial Agents
Inflammation
Antibodies
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chlamydia pneumoniae and atherosclerosis. / Rutherford, J. D.

In: Current Atherosclerosis Reports, Vol. 2, No. 3, 05.2000, p. 218-225.

Research output: Contribution to journalArticle

@article{63d779f504a049ca93a340f2d73033c2,
title = "Chlamydia pneumoniae and atherosclerosis.",
abstract = "Chlamydia pneumoniae (C. pneumoniae) is a common respiratory pathogen. Many reports have documented the presence of C. pneumoniae in atheromatous coronary arteries, aorta, carotid arteries, and peripheral arteries using a variety of techniques. There is clear experimental evidence that C. pneumoniae can infect macrophages, endothelial cells, smooth muscle cells, and induce the formation of foam cells. Evidence from basic research and epidemiologic studies suggest that C. pneumoniae can induce macrophage foam cell formation by dysregulating native LDL uptake or metabolism (or both). Relatively small, secondary prevention studies, have suggested that antibiotic therapy might reduce monocyte activation and C. pneumoniae antibody titers, reduce inflammatory markers and possibly reduce adverse cardiovascular events. It is possible that C. pneumoniae enhances atherogenesis by causing inflammation and eliciting immune responses and may be one of the factors contributing to this multifactorial disease process.",
author = "Rutherford, {J. D.}",
year = "2000",
month = "5",
language = "English (US)",
volume = "2",
pages = "218--225",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Chlamydia pneumoniae and atherosclerosis.

AU - Rutherford, J. D.

PY - 2000/5

Y1 - 2000/5

N2 - Chlamydia pneumoniae (C. pneumoniae) is a common respiratory pathogen. Many reports have documented the presence of C. pneumoniae in atheromatous coronary arteries, aorta, carotid arteries, and peripheral arteries using a variety of techniques. There is clear experimental evidence that C. pneumoniae can infect macrophages, endothelial cells, smooth muscle cells, and induce the formation of foam cells. Evidence from basic research and epidemiologic studies suggest that C. pneumoniae can induce macrophage foam cell formation by dysregulating native LDL uptake or metabolism (or both). Relatively small, secondary prevention studies, have suggested that antibiotic therapy might reduce monocyte activation and C. pneumoniae antibody titers, reduce inflammatory markers and possibly reduce adverse cardiovascular events. It is possible that C. pneumoniae enhances atherogenesis by causing inflammation and eliciting immune responses and may be one of the factors contributing to this multifactorial disease process.

AB - Chlamydia pneumoniae (C. pneumoniae) is a common respiratory pathogen. Many reports have documented the presence of C. pneumoniae in atheromatous coronary arteries, aorta, carotid arteries, and peripheral arteries using a variety of techniques. There is clear experimental evidence that C. pneumoniae can infect macrophages, endothelial cells, smooth muscle cells, and induce the formation of foam cells. Evidence from basic research and epidemiologic studies suggest that C. pneumoniae can induce macrophage foam cell formation by dysregulating native LDL uptake or metabolism (or both). Relatively small, secondary prevention studies, have suggested that antibiotic therapy might reduce monocyte activation and C. pneumoniae antibody titers, reduce inflammatory markers and possibly reduce adverse cardiovascular events. It is possible that C. pneumoniae enhances atherogenesis by causing inflammation and eliciting immune responses and may be one of the factors contributing to this multifactorial disease process.

UR - http://www.scopus.com/inward/record.url?scp=0034188750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034188750&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 218

EP - 225

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 3

ER -